BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 2015;61:712-21. [PMID: 25048716 DOI: 10.1002/hep.27323] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 15.6] [Reference Citation Analysis]
Number Citing Articles
1 Yu F, Zhang X, Tian S, Geng L, Xu W, Ma N, Wang M, Jia Y, Liu X, Ma J, Quan Y, Zhang C, Guo L, An W, Liu D. Comprehensive investigation of cytokine- and immune-related gene variants in HBV-associated hepatocellular carcinoma patients. Biosci Rep 2017;37:BSR20171263. [PMID: 29138264 DOI: 10.1042/BSR20171263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ciupe SM. Modeling the dynamics of hepatitis B infection, immunity, and drug therapy. Immunol Rev 2018;285:38-54. [PMID: 30129194 DOI: 10.1111/imr.12686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
3 Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns MP, Wedemeyer H; HepNet Acute HCV IV Study Group. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis 2017;17:215-22. [PMID: 28029529 DOI: 10.1016/S1473-3099(16)30408-X] [Cited by in Crossref: 74] [Cited by in F6Publishing: 23] [Article Influence: 12.3] [Reference Citation Analysis]
4 Dou Y, van Montfoort N, van den Bosch A, Janssen HLA, de Man RA, Buschow SI, Woltman AM. Elevated serum levels of soluble CD14 in HBeAg-positive chronic HBV patients upon Peginterferon treatment are associated with treatment response. J Viral Hepat 2019;26:1076-85. [PMID: 31090247 DOI: 10.1111/jvh.13127] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Nakajima M, Kobayashi S, Wada H, Tomokuni A, Takahashi H, Noda T, Matsui H, Matsukuma S, Kanekiyo S, Shindo Y, Tokumitsu Y, Nakagami Y, Suzuki N, Takeda S, Tanabe M, Ito K, Hoshii Y, Eguchi H, Nagano H. Viral elimination is essential for improving surgical outcomes of hepatitis C virus-related hepatocellular carcinoma: Multicenter retrospective analysis. Ann Gastroenterol Surg 2020;4:710-20. [PMID: 33319162 DOI: 10.1002/ags3.12377] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Liang Y, Yi P, Yuan DMK, Jie Z, Kwota Z, Soong L, Cong Y, Sun J. IL-33 induces immunosuppressive neutrophils via a type 2 innate lymphoid cell/IL-13/STAT6 axis and protects the liver against injury in LCMV infection-induced viral hepatitis. Cell Mol Immunol 2019;16:126-37. [PMID: 29400707 DOI: 10.1038/cmi.2017.147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
7 Sundberg I, Lannergård A, Ramklint M, Cunningham JL. Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. BMC Psychiatry 2018;18:157. [PMID: 29843679 DOI: 10.1186/s12888-018-1735-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
8 Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16:509-523. [PMID: 27374637 DOI: 10.1038/nri.2016.69] [Cited by in Crossref: 152] [Cited by in F6Publishing: 148] [Article Influence: 25.3] [Reference Citation Analysis]
9 Gill US, Kennedy PTF. The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics. J Viral Hepat 2018. [DOI: 10.1111/jvh.13040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
10 Jia ZH, Li YY, Wang JY, Zhang JY, Huang A, Guo XD, Zhu ZY, Wang FS, Wu XL. Activated γδ T cells exhibit cytotoxicity and the capacity for viral clearance in patients with acute hepatitis B. Clin Immunol 2019;202:40-8. [PMID: 30914281 DOI: 10.1016/j.clim.2019.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Balsitis S, Gali V, Mason PJ, Chaniewski S, Levine SM, Wichroski MJ, Feulner M, Song Y, Granaldi K, Loy JK, Thompson CM, Lesniak JA, Brockus C, Kishnani N, Menne S, Cockett MI, Iyer R, Mason SW, Tenney DJ. Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. PLoS One 2018;13:e0190058. [PMID: 29444087 DOI: 10.1371/journal.pone.0190058] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
12 Ballester-Ferré MP, Martínez F, Garcia-Gimeno N, Mora F, Serra MA. Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin. World J Hepatol 2017; 9(3): 161-166 [PMID: 28217253 DOI: 10.4254/wjh.v9.i3.161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
13 Liang X, Liu P, He Z, Chen X, Xiao X. The effect of maternal use of telbivudine on neonatal CD4+CD25+ regulatory T cells for the prevention of mother-to-child transmission of hepatitis B virus. Clin Res Hepatol Gastroenterol 2020;44:195-203. [PMID: 31257091 DOI: 10.1016/j.clinre.2019.06.004] [Reference Citation Analysis]
14 Shen XH, Xu P, Yu X, Song HF, Chen H, Zhang XG, Wu MY, Wang XF. Discrepant Clinical Significance of CD28+CD8- and CD4+CD25high Regulatory T Cells During the Progression of Hepatitis B Virus Infection. Viral Immunol 2018;31:548-58. [PMID: 30117787 DOI: 10.1089/vim.2018.0035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura YI, Dohi T, Shuno Y, Yano H, Mizokami M. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut 2018;67:362-71. [PMID: 27789659 DOI: 10.1136/gutjnl-2016-312653] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 23.8] [Reference Citation Analysis]
16 Ge J, Huang Z, Liu H, Chen J, Xie Z, Chen Z, Peng J, Sun J, Hou J, Zhang X. Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B. Front Immunol 2017;8:1173. [PMID: 29018442 DOI: 10.3389/fimmu.2017.01173] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
17 Banerjee P, Chakraborty A, Mondal RK, Khatun M, Datta S, Das K, Pandit P, Mukherjee S, Banerjee S, Ghosh S, Chakrabarti S, Chowdhury A, Datta S. HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy. Sci Rep 2017;7:44742. [PMID: 28303969 DOI: 10.1038/srep44742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Xu Y, Liu Y, Zhao M, Chen Y, Xie C, Gong M, Deng H, Li X, Sun J, Hou J, Wu H, Wang Z. Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy. Front Immunol 2017;8:1142. [PMID: 28959264 DOI: 10.3389/fimmu.2017.01142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Cannizzo ES, Tincati C, Binda F, Ronzi P, Cazzaniga FA, Antinori S, d'Arminio Monforte A, Marchetti G, Milazzo L. Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study. J Viral Hepat 2018;25:381-90. [PMID: 29091327 DOI: 10.1111/jvh.12820] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
20 Huang X, Glessner JT, Huang J, Zhou D, March ME, Wang H, Xia Q, Hakonarson H, Li J. Discovery of Novel Host Molecular Factors Underlying HBV/HCV Infection. Front Cell Dev Biol 2021;9:690882. [PMID: 34458256 DOI: 10.3389/fcell.2021.690882] [Reference Citation Analysis]
21 Chen J, Li Y, Lai F, Wang Y, Sutter K, Dittmer U, Ye J, Zai W, Liu M, Shen F, Wu M, Hu K, Li B, Lu M, Zhang X, Zhang J, Li J, Chen Q, Yuan Z. Functional Comparison of Interferon-α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon-α and Interferon-γ Signaling. Hepatology 2021;73:486-502. [PMID: 32333814 DOI: 10.1002/hep.31282] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
22 Hadziyannis SJ. Update on Hepatitis B Virus Infection: Focus on Treatment. J Clin Transl Hepatol 2014;2:285-91. [PMID: 26355326 DOI: 10.14218/JCTH.2014.00026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Mettke F, Schlevogt B, Deterding K, Wranke A, Smith A, Port K, Manns MP, Vogel A, Cornberg M, Wedemeyer H. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther. 2018;47:516-525. [PMID: 29205405 DOI: 10.1111/apt.14427] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 9.6] [Reference Citation Analysis]
24 Hellerbrand C, Schattenberg JM, Peterburs P, Lechner A, Brignoli R. The potential of silymarin for the treatment of hepatic disorders. Clin Phytosci 2017;2. [DOI: 10.1186/s40816-016-0019-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
25 Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection - an update. Microb Cell 2016;3:420-37. [PMID: 28357379 DOI: 10.15698/mic2016.09.527] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
26 Xiao Y, Xu H, Guo W, Zhao Y, Luo Y, Wang M, He Z, Ding Z, Liu J, Deng L, Sha F, Ma X. Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. Mol Biomed 2020;1:16. [PMID: 34765999 DOI: 10.1186/s43556-020-00017-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
28 Maini MK, Pallett LJ. Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. Lancet Gastroenterol Hepatol 2018;3:192-202. [PMID: 29870733 DOI: 10.1016/S2468-1253(18)30007-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 35] [Article Influence: 12.5] [Reference Citation Analysis]
29 Hutchinson JA, Weigand K, Adenugba A, Kronenberg K, Haarer J, Zeman F, Riquelme P, Hornung M, Ahrens N, Schlitt HJ, Geissler EK, Werner JM. Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers. Front Immunol 2018;9:146. [PMID: 29467758 DOI: 10.3389/fimmu.2018.00146] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Deng G, Ge J, Liu C, Pang J, Huang Z, Peng J, Sun J, Hou J, Zhang X. Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy. Clin Res Hepatol Gastroenterol 2017;41:386-98. [PMID: 28236535 DOI: 10.1016/j.clinre.2016.12.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
31 Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. Journal of Hepatology 2016;64:S117-31. [DOI: 10.1016/j.jhep.2016.02.016] [Cited by in Crossref: 120] [Cited by in F6Publishing: 112] [Article Influence: 20.0] [Reference Citation Analysis]
32 Fierro NA, González-Aldaco K, Torres-Valadez R, Trujillo-Trujillo ME, Roman S, Trujillo-Ochoa JL, Panduro A. Spontaneous hepatitis C viral clearance and hepatitis C chronic infection are associated with distinct cytokine profiles in Mexican patients. Mem Inst Oswaldo Cruz. 2015;110:267-271. [PMID: 25946254 DOI: 10.1590/0074-02760140377] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
33 Burwitz BJ, Hashiguchi PK, Mansouri M, Meyer C, Gilbride RM, Biswas S, Womack JL, Reed JS, Wu HL, Axthelm MK, Hansen SG, Picker LJ, Früh K, Sacha JB. MHC-E-Restricted CD8+ T Cells Target Hepatitis B Virus-Infected Human Hepatocytes. J Immunol 2020;204:2169-76. [PMID: 32161099 DOI: 10.4049/jimmunol.1900795] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Stelma F, van der Ree MH, Jansen L, Peters MW, Janssen HLA, Zaaijer HL, Takkenberg RB, Reesink HW. HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up. J Viral Hepat 2017;24:1107-13. [PMID: 28632898 DOI: 10.1111/jvh.12738] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
35 Kratzer R, Sansas B, Lélu K, Evlachev A, Schmitt D, Silvestre N, Inchauspé G, Martin P. A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model. Hum Vaccin Immunother 2018;14:1417-22. [PMID: 29388874 DOI: 10.1080/21645515.2018.1433970] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
36 Bender D, Hildt E. Effect of Hepatitis Viruses on the Nrf2/Keap1-Signaling Pathway and Its Impact on Viral Replication and Pathogenesis. Int J Mol Sci 2019;20:E4659. [PMID: 31546975 DOI: 10.3390/ijms20184659] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
37 Shemesh M, Lochte S, Piehler J, Schreiber G. IFNAR1 and IFNAR2 play distinct roles in initiating type I interferon-induced JAK-STAT signaling and activating STATs. Sci Signal 2021;14:eabe4627. [PMID: 34813358 DOI: 10.1126/scisignal.abe4627] [Reference Citation Analysis]
38 Van Tong H, Van Ba N, Hoan NX, Binh MT, Quyen DT, Son HA, Van Luong H, Quyet D, Meyer CG, Song LH, Toan NL, Velavan TP. Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases. BMC Infect Dis 2018;18:553. [PMID: 30419833 DOI: 10.1186/s12879-018-3473-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Debes JD, de Knegt RJ, Boonstra A. The Path to Cancer and Back: Immune Modulation During Hepatitis C Virus Infection, Progression to Fibrosis and Cancer, and Unexpected Roles of New Antivirals. Transplantation. 2017;101:910-915. [PMID: 28045877 DOI: 10.1097/tp.0000000000001623] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
40 Lee IC, Su CW, Lan KH, Wang YJ, Lee KC, Lin HC, Hou MC, Huang YH. Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. J Formos Med Assoc 2021;120:1676-85. [PMID: 33339708 DOI: 10.1016/j.jfma.2020.12.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Karimkhanilouyi S, Ghorbian S. Nucleic acid vaccines for hepatitis B and C virus. Infect Genet Evol. 2019;75:103968. [PMID: 31325609 DOI: 10.1016/j.meegid.2019.103968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
42 Murata K, Tsukuda S, Suizu F, Kimura A, Sugiyama M, Watashi K, Noguchi M, Mizokami M. Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection. Hepatology 2020;71:1533-45. [PMID: 31529730 DOI: 10.1002/hep.30956] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
43 Wu CS, Zhao Q, Zhang J, Wang JW, Qian Y, Fan YC, Wang K. Methylation status of the stimulator of interferon genes promoter in patients with chronic hepatitis B. Medicine (Baltimore) 2018;97:e13904. [PMID: 30593207 DOI: 10.1097/MD.0000000000013904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
44 Stevenson TJ, Barbour Y, McMahon BJ, Townshend-Bulson L, Hewitt AM, Espera HGF, Homan C, Holck P, Luna SV, Knall C, Simons BC. Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection. Open Forum Infect Dis 2019;6:ofz223. [PMID: 31249845 DOI: 10.1093/ofid/ofz223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
45 Hengst J, Falk CS, Schlaphoff V, Deterding K, Manns MP, Cornberg M, Wedemeyer H. Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. J Infect Dis. 2016;214:1965-1974. [PMID: 27683821 DOI: 10.1093/infdis/jiw457] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 12.7] [Reference Citation Analysis]
46 Block TM, Locarnini S, McMahon BJ, Rehermann B, Peters MG. Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics. Clin Infect Dis 2017;64:1283-8. [PMID: 28200098 DOI: 10.1093/cid/cix129] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
47 Lebossé F, Testoni B, Fresquet J, Facchetti F, Galmozzi E, Fournier M, Hervieu V, Berthillon P, Berby F, Bordes I, Durantel D, Levrero M, Lampertico P, Zoulim F. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. Journal of Hepatology 2017;66:897-909. [DOI: 10.1016/j.jhep.2016.12.024] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 15.2] [Reference Citation Analysis]
48 Suslov A, Wieland S, Menne S. Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B. Curr Opin Virol. 2018;30:9-17. [PMID: 29444493 DOI: 10.1016/j.coviro.2018.01.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
49 Essa S, Al-Attiyah R, Siddique I, Al-Nakib W. Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease. Med Princ Pract 2021;30:168-77. [PMID: 32966988 DOI: 10.1159/000511783] [Reference Citation Analysis]
50 Zhang Z, Wang C, Liu Z, Zou G, Li J, Lu M. Host Genetic Determinants of Hepatitis B Virus Infection. Front Genet. 2019;10:696. [PMID: 31475028 DOI: 10.3389/fgene.2019.00696] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
51 Zhou Y, Li S, Tang Z, Xu C, Huang S, Wu J, Dittmer U, Dickow J, Sutter K, Lu M, Yang D, Song J. Different antiviral effects of IFNα and IFNβ in an HBV mouse model. Immunobiology 2017;222:562-70. [PMID: 27839836 DOI: 10.1016/j.imbio.2016.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
52 Jung MK, Shin EC. Regulatory T Cells in Hepatitis B and C Virus Infections. Immune Netw 2016;16:330-6. [PMID: 28035208 DOI: 10.4110/in.2016.16.6.330] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
53 Wang D, Fu B, Shen X, Guo C, Liu Y, Zhang J, Sun R, Ye Y, Li J, Tian Z, Wei H. Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy. Signal Transduct Target Ther 2021;6:376. [PMID: 34737296 DOI: 10.1038/s41392-021-00776-0] [Reference Citation Analysis]
54 Yao Z, Qiao Y, Li X, Chen J, Ding J, Bai L, Shen F, Shi B, Liu J, Peng L, Li J, Yuan Z. Exosomes Exploit the Virus Entry Machinery and Pathway To Transmit Alpha Interferon-Induced Antiviral Activity. J Virol 2018;92:e01578-18. [PMID: 30282711 DOI: 10.1128/JVI.01578-18] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
55 Block TM, Alter H, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten TF, Guo JT, Hoshida Y, Kowdley KV, Li W, Lok AS, McMahon B, Mehta A, Perrillo R, Rice CM, Rinaudo J, Schinazi RF, Shetty K. Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop. Antiviral Res 2018;150:93-100. [PMID: 29248746 DOI: 10.1016/j.antiviral.2017.12.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
56 Forde J, Ciupe S, Cintron-arias A, Lenhart S. Optimal Control of Drug Therapy in a Hepatitis B Model. Applied Sciences 2016;6:219. [DOI: 10.3390/app6080219] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Cao WH, Li MH, Pan CQ, Lu Y, Zhang L, Ran CP, Wu SL, Hua WH, Liu SA, Shen G, Chang M, Liu RY, Hao HX, Hu LP, Xie Y. Quantitation of Plasmacytoid Dendritic Cells in Chronic Hepatitis B Patients with HBeAg Positivity During PEG-IFN and Entecavir Therapy. J Interferon Cytokine Res 2018;38:197-205. [PMID: 29791282 DOI: 10.1089/jir.2018.0014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
58 Tan N, Luo H, Kang Q, Pan JL, Cheng R, Xi HL, Chen HY, Han YF, yang YP, Xu XY. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases 2021; 9(21): 5812-5821 [PMID: 34368300 DOI: 10.12998/wjcc.v9.i21.5812] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Yang Q, Li XP, Zhong YB, Xiang TX, Zhang LL. Interferon-α inhibits cell migration and invasion and induces the expression of antiviral proteins in Huh-7 cells transfected with hepatitis B virus X gene-expressing lentivirus. Exp Ther Med 2017;14:5924-30. [PMID: 29285141 DOI: 10.3892/etm.2017.5288] [Reference Citation Analysis]
60 Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, Liang TJ, Ghany M, Rehermann B. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology. 2015;149:190-200.e2. [PMID: 25754160 DOI: 10.1053/j.gastro.2015.03.004] [Cited by in Crossref: 170] [Cited by in F6Publishing: 160] [Article Influence: 24.3] [Reference Citation Analysis]
61 Fox LE, Locke MC, Lenschow DJ. Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease. Front Immunol 2020;11:606874. [PMID: 33408718 DOI: 10.3389/fimmu.2020.606874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Fletcher SP, Chin DJ, Gruenbaum L, Bitter H, Rasmussen E, Ravindran P, Swinney DC, Birzele F, Schmucki R, Lorenz SH, Kopetzki E, Carter J, Triyatni M, Thampi LM, Yang J, AlDeghaither D, Murreddu MG, Cote P, Menne S. Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS Pathog 2015;11:e1005103. [PMID: 26352406 DOI: 10.1371/journal.ppat.1005103] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
63 Chen J, Wu M, Liu K, Zhang W, Li Y, Zhou X, Bai L, Yuan Z. New insights into hepatitis B virus biology and implications for novel antiviral strategies. National Science Review 2015;2:296-313. [DOI: 10.1093/nsr/nwv044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
64 Chang KM, Liu M. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Curr Opin Pharmacol 2016;30:93-105. [PMID: 27570126 DOI: 10.1016/j.coph.2016.07.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
65 Tjwa ET, Zoutendijk R, van Oord GW, Boeijen LL, Reijnders JG, van Campenhout MJ, de Knegt RJ, Janssen HL, Woltman AM, Boonstra A. Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF). Antiviral Research 2016;132:70-5. [DOI: 10.1016/j.antiviral.2016.05.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
66 Bertoletti A, Tan AT, Koh S. T-cell therapy for chronic viral hepatitis. Cytotherapy 2017;19:1317-24. [DOI: 10.1016/j.jcyt.2017.07.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
67 Pastuch-Gawołek G, Gillner D, Król E, Walczak K, Wandzik I. Selected nucleos(t)ide-based prescribed drugs and their multi-target activity. Eur J Pharmacol 2019;865:172747. [PMID: 31634460 DOI: 10.1016/j.ejphar.2019.172747] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
68 Yin W, Tong S, Zhang Q, Shao J, Liu Q, Peng H, Hu H, Peng M, Hu P, Ren H, Tian Z, Zhang D. Functional dichotomy of Vδ2 γδ T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-γ production. Sci Rep 2016;6:26296. [PMID: 27192960 DOI: 10.1038/srep26296] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
69 Aghabi YO, Yasin A, Kennedy JI, Davies SP, Butler AE, Stamataki Z. Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer. Front Immunol 2021;12:662134. [PMID: 33953725 DOI: 10.3389/fimmu.2021.662134] [Reference Citation Analysis]
70 Ghany MG, Feld JJ, Chang KM, Chan HLY, Lok ASF, Visvanathan K, Janssen HLA. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol Hepatol 2020;5:406-17. [PMID: 32057301 DOI: 10.1016/S2468-1253(19)30344-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
71 Zheng J, Ou Z, Lin X, Wang L, Liu Y, Jin S, Wu J. Analysis of epitope-based vaccine candidates against the E antigen of the hepatitis B virus based on the B genotype sequence: An in silico and in vitro approach. Cell Immunol 2018;329:56-65. [PMID: 29724463 DOI: 10.1016/j.cellimm.2018.04.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Agrawal B, Kumar R. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses. World J Gastroenterol 2016; 22(25): 5623-5626 [PMID: 27433078 DOI: 10.3748/wjg.v22.i25.5623] [Reference Citation Analysis]
73 Rehermann B. Natural Killer Cells in Viral Hepatitis. Cell Mol Gastroenterol Hepatol 2015;1:578-88. [PMID: 26682281 DOI: 10.1016/j.jcmgh.2015.09.004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
74 Meier-Stephenson V, Bremner WTR, Dalton CS, van Marle G, Coffin CS, Patel TR. Comprehensive Analysis of Hepatitis B Virus Promoter Region Mutations. Viruses 2018;10:E603. [PMID: 30388827 DOI: 10.3390/v10110603] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
75 Levrero M, Testoni B, Zoulim F. HBV cure: why, how, when? Curr Opin Virol. 2016;18:135-143. [PMID: 27447092 DOI: 10.1016/j.coviro.2016.06.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
76 Heymann F, Tacke F. Immunology in the liver--from homeostasis to disease. Nat Rev Gastroenterol Hepatol. 2016;13:88-110. [PMID: 26758786 DOI: 10.1038/nrgastro.2015.200] [Cited by in Crossref: 524] [Cited by in F6Publishing: 477] [Article Influence: 87.3] [Reference Citation Analysis]
77 De Re V, De Zorzi M, Caggiari L, Lauletta G, Tornesello ML, Fognani E, Miorin M, Racanelli V, Quartuccio L, Gragnani L, Russi S, Pavone F, Ghersetti M, Costa EG, Casarin P, Bomben R, Mazzaro C, Basaglia G, Berretta M, Vaccher E, Izzo F, Buonaguro FM, De Vita S, Zignego AL, De Paoli P, Dolcetti R. HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. Oncotarget 2016;7:37487-97. [PMID: 27183918 DOI: 10.18632/oncotarget.9303] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
78 Naylor PH, Mutchnick MG. Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach. J Viral Hepat 2018;25:4-9. [DOI: 10.1111/jvh.12807] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
79 Jiang DK, Wu X, Qian J, Ma XP, Yang J, Li Z, Wang R, Sun L, Liu F, Zhang P, Zhu X, Wu J, Chen K, Conran C, Zheng SL, Lu D, Yu L, Liu Y, Xu J. Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2016;63:1102-11. [PMID: 26704347 DOI: 10.1002/hep.28423] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
80 Yu J, Liu J, Ma CB, Qi L, Du Y, Hu X, Jiang Y, Zhou M, Wang E. Signal-On Electrochemical Detection for Drug-Resistant Hepatitis B Virus Mutants through Three-Way Junction Transduction and Exonuclease III-Assisted Catalyzed Hairpin Assembly. Anal Chem 2021. [PMID: 34920663 DOI: 10.1021/acs.analchem.1c03451] [Reference Citation Analysis]
81 Takaki A, Yagi T, Yamamoto K. Contradictory immune response in post liver transplantation hepatitis B and C. Int J Inflam 2014;2014:814760. [PMID: 25215259 DOI: 10.1155/2014/814760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
82 Hayes CN, Zhang P, Zhang Y, Chayama K. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection. Viruses. 2018;10. [PMID: 30274202 DOI: 10.3390/v10100531] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
83 Healy K, Pasetto A, Sobkowiak MJ, Soon CF, Cornberg M, Aleman S, Sällberg Chen M. Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies. Cells 2020;9:E1471. [PMID: 32560123 DOI: 10.3390/cells9061471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Zhang C, Hua R, Cui Y, Wang S, Yan H, Li D, Zhang Y, Tu Z, Hao P, Chen X, Zhong J, Niu J, Jin X. Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance. PLoS One 2017;12:e0171217. [PMID: 28170421 DOI: 10.1371/journal.pone.0171217] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
85 Isorce N, Lucifora J, Zoulim F, Durantel D. Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies. Antiviral Res. 2015;122:69-81. [PMID: 26275801 DOI: 10.1016/j.antiviral.2015.08.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
86 Zhang QF, Shao JY, Yin WW, Xia Y, Chen L, Wang X, Hu HD, Hu P, Ren H, Zhang DZ. Altered Immune Profiles of Natural Killer Cells in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0160171. [PMID: 27513564 DOI: 10.1371/journal.pone.0160171] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
87 Tong S, Liu G, Li M, Li X, Liu Q, Peng H, Li S, Ren H, Yin W. Natural killer cell activation contributes to hepatitis B viral control in a mouse model. Sci Rep 2017;7:314. [PMID: 28331190 DOI: 10.1038/s41598-017-00387-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
88 Pfaender S, von Hahn T, Steinmann J, Ciesek S, Steinmann E. Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy. Rev Med Virol 2016;26:330-9. [PMID: 27185010 DOI: 10.1002/rmv.1890] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
89 Chen T, Zhu L, Shi A, Ding L, Zhang X, Tan Z, Guo W, Yan W, Han M, Jia J, Luo X, Schuppan D, Ning Q. Functional restoration of CD56bright NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B. Hepatol Int 2017;11:419-28. [PMID: 28639033 DOI: 10.1007/s12072-017-9803-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
90 Hoan NX, Van Tong H, Giang DP, Cuong BK, Toan NL, Wedemeyer H, Bock CT, Kremsner PG, Song LH, Velavan TP. SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B. Oncotarget 2017;8:17127-39. [PMID: 28179578 DOI: 10.18632/oncotarget.15083] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
91 Boeijen LL, Hou J, de Groen RA, Verbon A, Boonstra A. Persistent Replication of HIV, Hepatitis C Virus (HCV), and HBV Results in Distinct Gene Expression Profiles by Human NK Cells. J Virol 2019;93:e00575-18. [PMID: 30185599 DOI: 10.1128/JVI.00575-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
92 Rouse BT, Mueller SN. Some vexations that challenge viral immunology. F1000Res 2016;5:F1000 Faculty Rev-1015. [PMID: 27303640 DOI: 10.12688/f1000research.8391.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
93 Yu F, Ma N, Zhang X, Tian S, Geng L, Xu W, Wang M, Jia Y, Liu X, Ma J, Quan Y, Zhang C, Guo L, An W, Liu D. Comprehensive investigating of cytokine and receptor related genes variants in patients with chronic hepatitis B virus infection. Cytokine 2018;103:10-4. [PMID: 29287219 DOI: 10.1016/j.cyto.2017.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
94 Yamamoto N, Sato Y, Munakata T, Kakuni M, Tateno C, Sanada T, Hirata Y, Murakami S, Tanaka Y, Chayama K, Hatakeyama H, Hyodo M, Harashima H, Kohara M. Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. Journal of Hepatology 2016;64:547-55. [DOI: 10.1016/j.jhep.2015.10.014] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
95 Brar TS, Hilgenfeldt E, Soldevila-pico C. Etiology and Pathogenesis of Hepatocellular Carcinoma. In: Liu C, editor. Precision Molecular Pathology of Liver Cancer. Cham: Springer International Publishing; 2018. pp. 1-15. [DOI: 10.1007/978-3-319-68082-8_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
96 Chang KM, Traum D, Park JJ, Ho S, Ojiro K, Wong DK, Wahed AS, Terrault NA, Khalili M, Sterling RK, Janssen HLA, Shuhart MC, Lau DT, Roberts LR, Johnson GS, Kaplan DE, Betts MR, Lee WM, Lok ASF; Hepatitis B Research Network (HBRN). Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B. PLoS Pathog 2019;15:e1007715. [PMID: 30998783 DOI: 10.1371/journal.ppat.1007715] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
97 Hoan NX, Van Tong H, Giang DP, Toan NL, Meyer CG, Bock CT, Kremsner PG, Song LH, Velavan TP. Interferon-stimulated gene 15 in hepatitis B-related liver diseases. Oncotarget. 2016;7:67777-67787. [PMID: 27626177 DOI: 10.18632/oncotarget.11955] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
98 Huang Z, Ge J, Pang J, Liu H, Chen J, Liao B, Huang X, Zuo D, Sun J, Lu M, Zhang X, Hou J. Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy. Antiviral Research 2015;118:10-9. [DOI: 10.1016/j.antiviral.2015.03.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
99 Ji J, Zhang Y, Fan Y. TIPE2 as a potential therapeutic target in chronic viral hepatitis. Expert Opinion on Therapeutic Targets 2019;23:485-93. [DOI: 10.1080/14728222.2019.1608948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
100 Fan YC, Zhang YY, Wang N, Sun YY, Wang K. Tumor necrosis factor-α-induced protein 8-like 2 (TIPE2) is associated with immune phases of patients with chronic hepatitis B. Oncotarget 2017;8:30781-92. [PMID: 28390195 DOI: 10.18632/oncotarget.15683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
101 Wang Q, Yu CR. Association between liver targeted antiviral therapy in colorectal cancer and survival benefits: An appraisal. World J Clin Cases 2020; 8(11): 2111-2115 [PMID: 32548140 DOI: 10.12998/wjcc.v8.i11.2111] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Li S, Li N, Yang S, Deng H, Li Y, Wang Y, Yang J, Lv J, Dong L, Yu G, Hou X, Wang G. The study of immune checkpoint inhibitors in chronic hepatitis B virus infection. International Immunopharmacology 2022;109:108842. [DOI: 10.1016/j.intimp.2022.108842] [Reference Citation Analysis]
103 Zhang S, Sun F, Ren T, Duan Y, Gu H, Lai C, Wang Z, Zhang P, Wang X, Yang P. Immunogenicity of an influenza virus-vectored vaccine carrying the hepatitis C virus protein epitopes in mice. Antiviral Res 2017;145:168-74. [PMID: 28778831 DOI: 10.1016/j.antiviral.2017.07.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
104 Testoni B, Durantel D, Zoulim F. Novel targets for hepatitis B virus therapy. Liver Int. 2017;37 Suppl 1:33-39. [PMID: 28052622 DOI: 10.1111/liv.13307] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
105 Torres-Cornejo A, Lauer GM. Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines. Pathog Immun 2017;2:102-25. [PMID: 28664194 DOI: 10.20411/pai.v2i1.201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
106 Agrawal T, Gaggar A, Subramanian M, Kottilil S, Choudhary A, Rao PN, Shah S, Trehanpati N. PNPLA3 polymorphisms are associated with raised alanine aminotransferase levels in hepatitis C virus genotype 3. Arab J Gastroenterol 2020;21:267-72. [PMID: 33071176 DOI: 10.1016/j.ajg.2020.09.002] [Reference Citation Analysis]
107 Thomas E, Baumert TF. Hepatitis B Virus-Hepatocyte Interactions and Innate Immune Responses: Experimental Models and Molecular Mechanisms. Semin Liver Dis 2019;39:301-14. [PMID: 31266064 DOI: 10.1055/s-0039-1685518] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]